Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free CORZZ Stock Alerts

Core Scientific (CORZZ) Financials

Core Scientific logo
$24.50 +2.11 (+9.42%)
Closing price 05/6/2026 03:58 PM Eastern
Extended Trading
$24.54 +0.04 (+0.16%)
As of 05/6/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Core Scientific

Annual Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -18 47 -2,146 -246 -1,438 -289
Consolidated Net Income / (Loss)		 -12 47 -2,146 -246 -1,438 -289
Net Income / (Loss) Continuing Operations		 -18 47 -2,146 -246 -1,438 -289
Total Pre-Tax Income 		-12 63 -2,163 -246 -1,437 -288
Total Operating Income		 -6.33 131 -2,110 8.96 -142 -246
Total Gross Profit		 9.39 239 8.40 123 121 38
Total Revenue		 54 544 640 502 511 319
Operating Revenue		 54 544 640 502 511 319
Total Cost of Revenue		 51 306 632 379 403 281
Operating Cost of Revenue		 51 306 632 379 403 281
Total Operating Expenses		 16 107 2,118 114 249 283
Selling, General & Admin Expense		 15 60 213 108 114 159
Other Operating Expenses / (Income)		 - 0.00 0.00 0.03 8.63 103
Impairment Charge		 0.00 37 1,881 4.41 123 11
Other Special Charges / (Income)		 -5.88 -2.06 -16 1.96 4.21 9.68
Total Other Income / (Expense), net		 -5.88 -68 -54 -255 -1,295 -42
Interest Expense		 1.33 8.02 0.29 -20 0.49 1.93
Interest & Investment Income		 -4.44 -44 -97 -86 -37 3.28
Other Income / (Expense), net		 -0.11 -16 43 -189 -1,257 -44
Income Tax Expense		 0.00 16 -17 0.68 0.86 0.58
Basic Earnings per Share		 ($0.14) $0.23 ($6.30) ($0.65) ($4.87) ($0.88)
Weighted Average Basic Shares Outstanding		 157.60M 207.26M 340.65M 379.86M 255.83M 318.07M
Diluted Earnings per Share		 ($0.14) $0.20 ($6.30) ($0.65) ($4.87) ($0.88)
Weighted Average Diluted Shares Outstanding		 157.60M 233.31M 340.65M 379.86M 255.83M 318.07M
Weighted Average Basic & Diluted Shares Outstanding		 - 0.00 373.80M 177.60M 294.12M 315.33M

Quarterly Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.26 -41 -196 211 -902 -455 -266 576 -937 -144 214
Consolidated Net Income / (Loss)		 -9.26 -41 -196 211 -902 -455 -266 576 -937 -144 214
Net Income / (Loss) Continuing Operations		 -9.26 -41 -196 211 -902 -455 -266 576 -937 -144 214
Total Pre-Tax Income 		-9.13 -41 -195 211 -902 -455 -265 576 -937 -144 214
Total Operating Income		 9.47 -12 3.93 55 -91 -41 -40 -47 -26 -55 -119
Total Gross Profit		 37 15 39 78 39 -0.16 4.76 8.21 5.03 3.91 21
Total Revenue		 127 113 142 180 141 95 94 80 79 81 80
Operating Revenue		 127 113 142 180 141 95 94 80 79 81 80
Total Cost of Revenue		 90 97 103 102 102 96 90 71 74 77 59
Operating Cost of Revenue		 90 97 103 102 102 96 90 71 74 77 59
Total Operating Expenses		 27 27 35 23 129 41 44 55 31 59 140
Selling, General & Admin Expense		 24 24 24 17 31 40 36 45 57 69 -7.19
Other Operating Expenses / (Income)		 0.00 0.00 0.03 2.22 1.12 0.21 0.26 11 -30 -11 133
Other Special Charges / (Income)		 -0.76 -0.02 3.80 3.82 -0.27 0.51 0.15 0.01 4.17 0.30 2.58
Total Other Income / (Expense), net		 -19 -29 -199 156 -811 -414 -225 623 -910 -89 334
Interest Expense		 0.00 -0.37 1.07 0.05 0.12 0.32 - 0.00 1.38 0.00 0.56
Interest & Investment Income		 0.04 -2.20 -84 -14 -15 -7.07 -1.14 2.19 1.19 0.82 -0.92
Other Income / (Expense), net		 -19 -27 -114 170 -796 -407 -224 621 -910 -90 335
Income Tax Expense		 0.13 0.11 0.34 0.21 0.14 0.13 0.38 0.21 0.16 0.13 0.10
Basic Earnings per Share		 ($0.02) ($0.11) ($0.52) $0.91 ($5.05) ($1.17) $0.38 $1.42 ($0.04) ($0.45) ($1.82)
Weighted Average Basic Shares Outstanding		 375.78M 382.48M 379.86M 230.95M 178.51M 292.49M 255.83M 315.19M 317.99M 318.56M 318.07M
Diluted Earnings per Share		 ($0.02) ($0.11) ($0.52) $0.78 ($5.05) ($1.17) $0.51 $1.24 ($0.04) ($0.45) ($1.63)
Weighted Average Diluted Shares Outstanding		 375.78M 382.48M 379.86M 282.53M 178.51M 292.49M 255.83M 363.31M 317.99M 318.56M 318.07M
Weighted Average Basic & Diluted Shares Outstanding		 382.61M 386.02M 177.60M 177.78M 258.22M 279.25M 294.12M 297.82M 305.41M 310.06M 315.33M

Annual Cash Flow Statements for Core Scientific

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.81 123 -79 17 767 -526
Net Cash From Operating Activities		 -24 -57 205 65 43 278
Net Cash From Continuing Operating Activities		 -24 -57 205 65 43 278
Net Income / (Loss) Continuing Operations		 -12 47 -2,146 -246 -1,438 -289
Consolidated Net Income / (Loss)		 -12 47 -2,146 -246 -1,438 -289
Depreciation Expense		 9.40 33 225 96 113 69
Amortization Expense		 1.30 1.37 7.97 1.19 11 17
Non-Cash Adjustments To Reconcile Net Income		 4.95 -75 2,058 47 1,387 -44
Changes in Operating Assets and Liabilities, net		 -27 -64 60 167 -30 525
Net Cash From Investing Activities		 -15 -424 -591 -3.00 -95 -741
Net Cash From Continuing Investing Activities		 -15 -425 -591 -3.00 -95 -741
Purchase of Property, Plant & Equipment		 0.00 0.00 -384 -16 -95 -729
Acquisitions		 -14 -365 - -0.83 -0.23 -15
Sale of Property, Plant & Equipment		 - 0.00 0.00 14 0.00 3.46
Net Cash From Financing Activities		 41 604 306 -45 820 -63
Net Cash From Continuing Financing Activities		 41 604 306 -45 820 -63
Repayment of Debt		 -7.10 -49 -113 -41 -309 -36
Issuance of Debt		 45 671 261 0.00 1,078 0.00
Issuance of Common Equity		 - - 0.00 0.00 55 0.00
Other Financing Activities, net		 2.64 -18 190 -3.66 -4.54 -27

Quarterly Cash Flow Statements for Core Scientific

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 7.47 -13 5.77 45 -17 157 583 -138 -117 -128 -142
Net Cash From Operating Activities		 18 5.43 22 22 1.20 5.71 14 -45 34 132 153
Net Cash From Continuing Operating Activities		 18 5.43 22 22 1.20 5.71 14 -45 34 132 153
Net Income / (Loss) Continuing Operations		 -9.26 -41 -196 211 -805 -455 -266 576 -937 -147 214
Consolidated Net Income / (Loss)		 -9.26 -41 -196 211 -805 -455 -266 576 -937 -147 214
Depreciation Expense		 20 24 31 29 29 29 26 20 19 16 14
Amortization Expense		 0.27 0.23 0.49 1.43 2.45 2.29 4.51 4.41 4.36 4.16 4.34
Non-Cash Adjustments To Reconcile Net Income		 14 15 26 -199 807 431 225 -662 848 39 -269
Changes in Operating Assets and Liabilities, net		 -7.58 7.52 159 -20 -33 -1.46 24 17 100 219 189
Net Cash From Investing Activities		 -0.62 -2.87 2.36 -32 -3.18 -31 -29 -89 -120 -254 -273
Net Cash From Continuing Investing Activities		 -0.62 -2.87 2.36 -32 -3.18 -31 -29 -89 -120 -254 -273
Purchase of Property, Plant & Equipment		 -0.95 -2.87 -12 -32 -3.14 -31 -29 -84 -121 -244 -275
Acquisitions		 - - - 0.00 - - - -5.00 - -10 -0.05
Sale of Property, Plant & Equipment		 - - - - - - - - - 0.26 1.53
Net Cash From Financing Activities		 -9.95 -15 -18 54 -15 182 598 -4.20 -32 -5.32 -22
Net Cash From Continuing Financing Activities		 -9.95 -15 -18 54 -15 182 598 -4.20 -32 -5.32 -22
Repayment of Debt		 -9.95 -12 -22 -14 -11 -271 -15 -3.96 -32 -1.67 1.02
Other Financing Activities, net		 - -3.41 3.41 -6.94 -4.10 6.01 2.97 -0.24 -0.25 -3.65 -23

Annual Balance Sheets for Core Scientific

This table presents Core Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.02 2,439 808 712 1,476 2,348
Total Current Assets		 0.00 757 85 97 904 896
Cash & Equivalents		 0.00 118 16 50 836 311
Restricted Cash		 - 14 36 19 0.78 0.00
Other Current Assets		 - 593 0.72 26 67 584
Plant, Property, & Equipment, net		 0.00 0.00 691 585 433 1,293
Total Noncurrent Assets		 0.02 1,682 31 30 139 159
Other Noncurrent Operating Assets		 0.02 618 30 30 139 159
Total Liabilities & Shareholders' Equity		 0.02 2,439 808 712 1,476 2,348
Total Liabilities		 0.00 1,053 1,217 1,309 2,419 3,310
Total Current Liabilities		 0.00 320 187 488 135 781
Accounts Payable		 0.00 12 54 155 19 126
Accrued Expenses		 0.00 68 18 180 65 512
Current Deferred Revenue		 - 136 78 9.83 18 128
Other Current Liabilities		 - 0.00 0.77 20 32 16
Total Noncurrent Liabilities		 0.00 733 1,030 821 2,284 2,529
Long-Term Debt		 - 652 0.00 684 1,074 1,060
Noncurrent Deferred Revenue		 - - - - 0.00 428
Other Noncurrent Operating Liabilities		 0.00 19 1,030 99 1,210 1,040
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.01 1,341 -409 -597 -943 -963
Total Preferred & Common Equity		 0.01 1,341 -409 -597 -943 -963
Preferred Stock		 0.00 - - 0.00 0.00 0.00
Total Common Equity		 0.01 1,341 -409 -597 -943 -963
Common Stock		 0.03 1,380 1,764 1,823 2,915 3,184
Retained Earnings		 -0.01 -27 -2,174 -2,420 -3,858 -4,147

Quarterly Balance Sheets for Core Scientific

This table presents Core Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 1,404 760 751 705 814 761 922 1,498 1,851 2,171
Total Current Assets		 214 100 111 135 143 118 278 833 1,005 1,061
Cash & Equivalents		 30 47 58 42 98 96 253 698 581 453
Restricted Cash		 8.10 22 19 22 16 0.98 0.78 0.78 0.00 0.00
Other Current Assets		 173 31 33 34 28 16 18 133 423 608
Plant, Property, & Equipment, net		 1,156 628 608 547 576 550 550 523 701 954
Total Noncurrent Assets		 34 32 32 23 95 94 94 142 145 156
Other Noncurrent Operating Assets		 33 30 29 21 93 94 94 142 145 156
Total Liabilities & Shareholders' Equity		 1,404 760 751 705 814 761 922 1,498 1,851 2,171
Total Liabilities		 1,331 1,169 1,143 1,124 1,132 1,845 1,651 1,807 3,043 3,424
Total Current Liabilities		 1,289 215 187 313 138 75 77 196 563 670
Accounts Payable		 44 50 54 46 16 8.49 6.50 6.33 215 212
Accrued Expenses		 102 59 41 56 68 29 32 95 181 358
Current Deferred Revenue		 87 70 64 63 9.25 7.91 9.94 61 150 84
Other Current Liabilities		 78 0.60 0.42 20 21 11 10 17 17 16
Total Noncurrent Liabilities		 42 954 956 812 994 1,771 1,575 1,611 2,480 2,754
Long-Term Debt		 0.00 - 0.05 680 557 527 475 1,072 1,058 1,059
Other Noncurrent Operating Liabilities		 42 953 955 95 368 1,176 1,035 445 1,422 1,695
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 73 -409 -392 -419 -319 -1,084 -729 -309 -1,192 -1,253
Total Preferred & Common Equity		 73 -409 -392 -419 -319 -1,084 -729 -309 -1,192 -1,253
Preferred Stock		 - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 73 -409 -392 -419 -319 -1,084 -729 -309 -1,192 -1,253
Common Stock		 1,739 1,777 1,791 1,806 1,891 1,931 2,740 2,973 3,027 3,110
Retained Earnings		 -1,739 -2,185 -2,183 -2,225 -2,210 -3,014 -3,470 -3,282 -4,219 -4,363

Annual Metrics And Ratios for Core Scientific

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - 620,122,600.00
DEI Adjusted Shares Outstanding		 - - - - - 620,122,600.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -0.47
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -4.43 99 -1,477 6.27 -13 -172
Return On Investment Capital (ROIC_SIMPLE)		 - - 396.55% 2.52% -3.65% -176.17%
Earnings before Interest and Taxes (EBIT)		 -6.44 115 -2,066 -180 -1,277 -289
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.27 150 -1,833 -82 -1,153 -203
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1,974 1,021 -597 635 -664
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.01 2,073 -425 179 -469 -214
Increase / (Decrease) in Invested Capital		 0.00 2,073 -2,497 604 -648 492
Book Value per Share		 $0.00 $31.10 ($1.09) ($1.55) ($2.94) ($3.11)
Tangible Book Value per Share		 $0.00 $6.43 ($1.10) ($1.55) ($2.94) ($3.11)
Total Capital		 0.01 2,204 -372 249 368 98
Total Debt		 0.00 819 37 846 1,188 1,060
Total Long-Term Debt		 0.00 714 0.72 721 1,172 1,060
Net Debt		 0.00 687 -15 776 351 749
Capital Expenditures (CapEx)		 0.00 0.00 384 3.00 95 726
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.00 409 -118 -337 -51 -197
Debt-free Net Working Capital (DFNWC)		 -0.00 541 -65 -267 786 114
Net Working Capital (NWC)		 -0.00 436 -102 -391 769 114
Net Nonoperating Expense (NNE)		 7.78 51 670 253 1,302 117
Net Nonoperating Obligations (NNO)		 0.00 687 -15 776 351 749
Total Depreciation and Amortization (D&A)		 11 35 233 97 124 86
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.83) ($6.30) ($0.65) ($4.39) ($0.88)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 316.24M 340.65M 379.86M 255.83M 318.07M
Adjusted Diluted Earnings per Share		 $0.00 ($0.83) ($6.30) ($0.65) ($4.39) ($0.88)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 316.24M 340.65M 379.86M 255.83M 318.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.83) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.50M 373.80M 177.60M 294.12M 315.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.55 125 -171 11 -10 -157
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Core Scientific

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 620,122,600.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 620,122,600.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.35
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 6.63 -8.43 2.75 55 4.61 -29 -28 -43 -18 -40 -119
Return On Investment Capital (ROIC_SIMPLE)		 - - 1.11% - - - -7.57% -4.25% 263.59% 58.30% -122.18%
Earnings before Interest and Taxes (EBIT)		 -9.17 -39 -110 225 -790 -448 -264 579 -936 -147 216
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 12 -15 -79 255 -758 -417 -233 603 -913 -127 234
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1,870 678 -601 -603 132 723 620 -128 1.69 57 -611
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -440 326 179 217 -568 -425 -469 303 -588 -522 -214
Increase / (Decrease) in Invested Capital		 -1,864 -687 604 659 -128 -751 -648 85 -20 -97 492
Book Value per Share		 ($1.04) ($1.09) ($1.55) ($1.79) ($6.10) ($2.82) ($2.94) ($0.62) ($3.57) ($3.69) ($3.11)
Tangible Book Value per Share		 ($1.05) ($1.10) ($1.55) ($1.81) ($6.10) ($2.82) ($2.94) ($0.62) ($3.57) ($3.69) ($3.11)
Total Capital		 -364 426 249 332 -471 -172 368 1,002 -6.98 -69 98
Total Debt		 29 845 846 650 613 558 1,188 1,183 1,058 1,059 1,060
Total Long-Term Debt		 1.08 717 721 627 594 540 1,172 1,167 1,058 1,059 1,060
Net Debt		 -48 781 776 536 516 304 351 484 476 606 749
Capital Expenditures (CapEx)		 0.95 2.87 12 32 3.14 31 29 88 121 244 273
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -125 -114 -337 -86 -36 -35 -51 -45 -139 -62 -197
Debt-free Net Working Capital (DFNWC)		 -48 -50 -267 29 61 219 786 654 442 391 114
Net Working Capital (NWC)		 -76 -178 -391 5.18 43 201 769 638 442 391 114
Net Nonoperating Expense (NNE)		 16 33 198 -156 810 426 238 -623 918 106 -333
Net Nonoperating Obligations (NNO)		 -48 745 776 536 516 304 351 484 476 606 749
Total Depreciation and Amortization (D&A)		 21 24 32 30 32 31 31 24 23 20 18
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.02) ($0.11) ($0.52) $0.91 ($4.51) ($1.17) $0.38 $1.44 ($0.04) ($0.46) ($1.82)
Adjusted Weighted Average Basic Shares Outstanding		 375.78M 382.48M 379.86M 230.95M 178.51M 292.49M 255.83M 315.19M 317.99M 318.56M 318.07M
Adjusted Diluted Earnings per Share		 ($0.02) ($0.11) ($0.52) $0.78 ($4.51) ($1.17) $0.51 $1.25 ($0.04) ($0.46) ($1.63)
Adjusted Weighted Average Diluted Shares Outstanding		 375.78M 382.48M 379.86M 282.53M 178.51M 292.49M 255.83M 363.31M 317.99M 318.56M 318.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 382.61M 386.02M 177.60M 177.78M 258.22M 279.25M 294.12M 297.82M 305.41M 310.06M 315.33M
Normalized Net Operating Profit after Tax (NOPAT)		 6.89 -7.97 6.49 59 4.42 -28 -28 -43 -15 -38 -117
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, investor-focused snapshot of Core Scientific (CORZ) using the last four fiscal years of quarterly data (2022–2025). The stories that stand out are a mix of improving cash flow in late 2025 driven by one-time items, a heavy capex footprint, and persistent operating and balance-sheet challenges.

  • Positive: Q4 2025 net cash from continuing operating activities was about $153.1 million, signaling a strong quarterly cash generator relative to several prior periods.
  • Positive: Q4 2025 other income / (expense), net totaled about $335.0 million, providing a substantial one-time boost to net income.
  • Revenue trended down over the period, declining from around $141.9 million in some 2023 quarters to the mid-to-high $70s–$80s million in 2024–2025, indicating ongoing headwinds.
  • Net income in Q4 2025 was reported at about $214.2 million, largely due to non-operating items rather than core operating performance, so sustainability is unclear.
  • Cash balances fluctuated: Cash & equivalents were about $581.3 million in mid-2025, dipping to roughly $453.4 million by Q3 2025, implying liquidity volatility.
  • Operating income has been negative in most quarters of 2023–2025 (Q4 2025 operating income around -$119.3 million), highlighting ongoing operating losses.
  • Recent equity lines show a persistent deficit: Total equity is negative in several reports (for example, Total Common Equity around -$1.25 billion in Q3 2025), signaling a continuing equity shortfall.
  • Debt load remains high, with long-term debt typically near $1.06–$1.07 billion in recent periods, underscoring a substantial leverage burden.
  • Capital expenditures have been sizable, with PPE purchases around $245–$275 million in several quarters (e.g., Q4 2025 PPE of about $274.8 million; Q3 2025 about $244.5 million; Q4 2024 about $289.9 million).
  • Financing cash flows have tended to be negative in multiple quarters, reflecting net outflows from financing activity (for example, Q4 2025 net cash from financing activities around -$21.8 million).
05/07/26 02:57 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Core Scientific's Financials

When does Core Scientific's fiscal year end?

According to the most recent income statement we have on file, Core Scientific's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Core Scientific's net income changed over the last 5 years?

Core Scientific's net income appears to be on an upward trend, with a most recent value of -$288.62 million in 2025, rising from -$12.21 million in 2020. The previous period was -$1.44 billion in 2024.

What is Core Scientific's operating income?
Core Scientific's total operating income in 2025 was -$245.59 million, based on the following breakdown:
  • Total Gross Profit: $37.90 million
  • Total Operating Expenses: $283.49 million
How has Core Scientific's revenue changed over the last 5 years?

Over the last 5 years, Core Scientific's total revenue changed from $54.19 million in 2020 to $319.02 million in 2025, a change of 488.7%.

How much debt does Core Scientific have?

Core Scientific's total liabilities were at $3.31 billion at the end of 2025, a 36.8% increase from 2024, and a 827,595,900.0% increase since 2020.

How much cash does Core Scientific have?

In the past 5 years, Core Scientific's cash and equivalents has ranged from $0.00 in 2020 to $836.20 million in 2024, and is currently $311.38 million as of their latest financial filing in 2025.

How has Core Scientific's book value per share changed over the last 5 years?

Over the last 5 years, Core Scientific's book value per share changed from 0.00 in 2020 to -3.11 in 2025, a change of -3,105,100.0%.


Related Companies

Financial statements for NASDAQ:CORZZ last updated on 3/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel